ATE331707T1 - 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor - Google Patents

4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor

Info

Publication number
ATE331707T1
ATE331707T1 AT02780760T AT02780760T ATE331707T1 AT E331707 T1 ATE331707 T1 AT E331707T1 AT 02780760 T AT02780760 T AT 02780760T AT 02780760 T AT02780760 T AT 02780760T AT E331707 T1 ATE331707 T1 AT E331707T1
Authority
AT
Austria
Prior art keywords
piperazinylindol
affinity
receptor
derivatives
piperazinylindol derivatives
Prior art date
Application number
AT02780760T
Other languages
English (en)
Inventor
Andrew John Briggs
Robin Douglas Clark
Ralph New Harris Iii
David Bruce Repke
Douglas Leslie Wren
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE331707T1 publication Critical patent/ATE331707T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT02780760T 2001-06-15 2002-06-06 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor ATE331707T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29883401P 2001-06-15 2001-06-15
US37874802P 2002-05-08 2002-05-08

Publications (1)

Publication Number Publication Date
ATE331707T1 true ATE331707T1 (de) 2006-07-15

Family

ID=26970893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02780760T ATE331707T1 (de) 2001-06-15 2002-06-06 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor

Country Status (15)

Country Link
US (1) US6790848B2 (de)
EP (1) EP1401812B1 (de)
JP (1) JP2005501019A (de)
KR (1) KR20040010709A (de)
AR (1) AR036057A1 (de)
AT (1) ATE331707T1 (de)
BR (1) BR0210411A (de)
CA (1) CA2450245A1 (de)
DE (1) DE60212841T2 (de)
ES (1) ES2268113T3 (de)
MX (1) MXPA03011638A (de)
PA (1) PA8547901A1 (de)
PE (1) PE20030119A1 (de)
UY (1) UY27336A1 (de)
WO (1) WO2002102774A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
CN1314669C (zh) * 2002-09-17 2007-05-09 弗·哈夫曼-拉罗切有限公司 2,7－取代的吲哚以及它们作为5－ht6调节剂的用途
JP2006515341A (ja) * 2003-03-03 2006-05-25 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６調節物質として使用するための２，５−および２，６−置換テトラヒドロイソキノリン
WO2004080407A2 (en) * 2003-03-07 2004-09-23 Predix Pharmaceuticals Holdings, Inc. New serotonin modulating compounds and uses therefor
JP2006525972A (ja) * 2003-05-09 2006-11-16 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 食物摂取障害の予防および／または治療用の医薬品製造のためのスルホンアミド誘導体の使用
ES2219181B1 (es) * 2003-05-09 2005-12-16 Laboratorios Del Dr. Esteve, S.A. Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias.
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
AU2005205016B2 (en) * 2004-01-16 2010-07-15 F. Hoffmann-La Roche Ag 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1799306B1 (de) 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur behandlung kognitiver störungen
US9216966B2 (en) 2004-10-04 2015-12-22 John Manfredi Compounds for Alzheimer's disease
US7678823B2 (en) * 2004-10-04 2010-03-16 Myriad Pharmaceticals, Inc. Compounds for alzheimer's disease
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
EP1984351A1 (de) * 2006-02-17 2008-10-29 Memory Pharmaceuticals Corporation Verbindungen mit 5-ht6-rezeptor-affinität
JP2009532501A (ja) * 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド 疾患および障害のための化合物
WO2008003703A1 (en) 2006-07-03 2008-01-10 Biovitrum Ab (Publ) Indoles as 5-ht6 modulators
MX2009004898A (es) 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
KR20100031578A (ko) * 2007-05-24 2010-03-23 메모리 파마슈티칼스 코포레이션 5-ｈｔ6 수용체 친화성을 갖는 4'-치환된 화합물
WO2009023844A2 (en) * 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-ht6 receptor affinity
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
EP2254564A1 (de) 2007-12-12 2010-12-01 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
WO2011088836A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS
US20120157494A1 (en) * 2010-12-16 2012-06-21 Harris Iii Ralph New Isoindolyl compounds
CA2821480A1 (en) 2010-12-20 2012-06-28 Astrazeneca Ab 2-carboxamide-4-piperazinyl-benzofuran derivative
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
AU2015286049B2 (en) * 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3911651B1 (de) * 2019-01-17 2024-01-10 ViiV Healthcare UK (No.4) Limited Verfahren zur herstellung von fostemsavir

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60190761A (ja) 1984-03-09 1985-09-28 Sagami Chem Res Center ４−アミノインド−ルの製造方法
EP0716650B1 (de) * 1993-09-03 1999-03-24 Smithkline Beecham Plc Indol- und indolin-derivate als 5ht1d rezeptor antagonisten
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
WO2001032660A1 (en) 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
EP1343756A2 (de) * 2000-11-02 2003-09-17 Wyeth 1-aryl- oder 1-alkylsulfonyl heterocyclylbenzazole als 5-hydroxytryptamin-6-liganden
ES2271124T3 (es) * 2000-11-24 2007-04-16 Smithkline Beecham Plc Compuestos indolil-sulfonilicos utiles en el tratamiento de trastornos del snc.

Also Published As

Publication number Publication date
DE60212841T2 (de) 2007-06-21
PE20030119A1 (es) 2003-02-13
EP1401812B1 (de) 2006-06-28
CA2450245A1 (en) 2002-12-27
KR20040010709A (ko) 2004-01-31
ES2268113T3 (es) 2007-03-16
EP1401812A1 (de) 2004-03-31
US6790848B2 (en) 2004-09-14
UY27336A1 (es) 2002-12-31
AR036057A1 (es) 2004-08-04
BR0210411A (pt) 2004-08-17
WO2002102774A1 (en) 2002-12-27
US20030045527A1 (en) 2003-03-06
MXPA03011638A (es) 2004-04-02
PA8547901A1 (es) 2003-12-10
JP2005501019A (ja) 2005-01-13
DE60212841D1 (de) 2006-08-10

Similar Documents

Publication Publication Date Title
DE60212841D1 (de) 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
DE60218037D1 (de) Neue indolderivate mit affinität zum 5-ht6-rezeptor
ATE344030T1 (de) 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
DE69928945D1 (de) 4,4-biarylpiperidinederivate mit opioid-receptor-wirkung
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
DE60132087D1 (de) Mechanismus zum einstellen der position
NO20013444L (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
NO20043064L (no) 1-alkyl-1-azoniabisyklo [2.2.2] oktankarbamatderivater og anvendelse av disse som muskarine reseptorantagonister
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
FI982066A0 (fi) Sylinterilukko-avain-yhdistelmä
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
DE60013564D1 (de) Mehrzweckventil
NO20041604L (no) 3-substituerte 4-pyrimidonderivater
ATE465995T1 (de) N-'(1,5-diphenyl-1h-pyrazol-3- yl)sulfonamidderivate mit affinität zum cb1- rezeptor
DE60040168D1 (de) Fluorelastomer-zusammensetzung zum vernetzen
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE326467T1 (de) Imidazo 1,2-aöpyridine
IS6431A (is) Fenýlpíperazínýl afleiður
NO20026168D0 (no) 3-azabicyklo(3.1.0)heksan derivater med opioid reseptor affinitet
NO20023172L (no) 10, 11-difluormetylendioksykamptoteciner med topoisomerase I inhibering
DE50015441D1 (de) Fadenliefergerät mit verstellbarer fadenleiteinrichtung
DE69926954D1 (de) Zuführventil
FI990684A0 (fi) Sauvakaavin
NO20006041D0 (no) N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer
FIU20000296U0 (fi) Mekanismi tuolin säätämiseksi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties